The FDA on May 15, 2025, approved ZYNYZ® with Carboplatin and Paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC). The FDA also approved ZYNYZ®, as a single agent, for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to Platinum-based chemotherapy. ZYNYZ® is a product of Incyte Corporation.
Bottom Ad
Advertisement
Subscribe
